BARCELONA—There was no improvement in biochemical progression free survival among patients who had their high-risk localized prostate cancers treated with elective pelvic nodal irradiation compared with those who had prostate radiation only. That was the finding of a sub-analysis of 358 patients from the GETUG 12 phase-III trial treated with primary radiotherapy. Study author Pierre Blanchard MD PhD, from Gustave Roussy in Villejuif, France, gave Oncology Times reporter Sarah Maxwell the details after he presented the results to the 3rd ESTRO Forum (April 24-28, 2015).
You may also like...
International Research and Consensus Needed to Interpret Breast Cancer Genomics Data 27 Mar, 2015 Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer 12 Feb, 2014 Building Health For All Capacity In Tanzania 30 Mar, 2012 Three Drug Regimen Best for Squamous Non Small Cell Lung Cancer—Even in Older Patients 20 Apr, 2015
- Previous story Combined Intracavitary/Interstitial Brachytherapy: New benchmark for Cervical Cancer
- Next story ARCON Improved Quality of Life in Advanced Laryngeal Cancer: Phase-III ARCON Trial
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014